Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.20.4
Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Contingent liabilities - Crystal    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Payment for contingent consideration liabilities   $ 1,800
Contingent liabilities - Icagen    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Payment for contingent consideration liabilities $ 500  
Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 363,567 998,324
Liabilities, fair value 49,193 9,017
Recurring | Contingent liabilities - Crystal    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 800 2,659
Recurring | Contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 508 348
Recurring | Contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 3,821 5,935
Recurring | Contingent liabilities - Icagen    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 6,404  
Recurring | Contingent liabilities - Pfenex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 37,600  
Recurring | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 60 75
Recurring | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 324,478 939,989
Recurring | Investment in Viking common stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 32,763 48,425
Recurring | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 6,326 9,910
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 42,527 61,408
Liabilities, fair value 60 75
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Crystal    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Icagen    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Pfenex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 60 75
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 3,438 3,073
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking common stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 32,763 48,425
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 6,326 9,910
Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 320,647 936,791
Liabilities, fair value 3,821 5,935
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Crystal    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 3,821 5,935
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Icagen    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0  
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Pfenex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0  
Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 320,647 936,791
Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking common stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 393 125
Liabilities, fair value 45,312 3,007
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Crystal    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 800 2,659
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 508 348
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Icagen    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 6,404  
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Pfenex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 37,600  
Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 393 125
Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking common stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 0 $ 0
Transferred over Time | Phase 3 Clinical Trial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Gross contract asset 10,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Gross contract asset $ 375,000